Navigation Links
MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease

dard of care."

The Phase 3 study was designed to compare the safety and efficacy of motavizumab with that of Synagis, which was first launched by MedImmune in 1998, in reducing serious RSV disease in high-risk infants in the inpatient and outpatient settings. As defined in the study, infants who are at high risk for RSV include those who were born at 35 weeks gestation or less as well as those who have chronic lung disease (CLD) due to being born prematurely. The primary endpoint was to assess the incidence of RSV hospitalizations with motavizumab compared to Synagis. Motavizumab met the primary endpoint, demonstrating non-inferiority to Synagis with 26 percent fewer RSV hospitalizations in motavizumab-treated infants. The overall RSV attack rate was low in both treatment groups: 1.4 percent for infants who received motavizumab, compared with 1.9 percent for those who received Synagis [RR: 0.740, 95 percent CI: (0.503, 1.083)]. The p-value for non-inferiority was p<0.01, demonstrating a significant finding.

Analysis of the data also showed that motavizumab reduced the incidence of RSV-specific medically attended outpatient LRIs (the study's RSV-related secondary endpoint) by approximately 50 percent compared with Synagis. The overall RSV-specific medically attended LRI rate was 2.0 percent for infants who received motavizumab compared with 3.9 percent for those who received Synagis (p<0.01). There were no significant differences in other non-RSV- specific endpoints.

"I am very pleased with the study results for motavizumab," said Xavier Carbonell, M.D., Ph.D., lead study author, chairman of neonatology, Barcelona Hospital Clinic, and vice president, Spanish Neonatal Society. "As a practicing neonatologist, I look forward to the potential to use this next- generation antibody to help reduce RSV-related hospitalizations and LRIs in the outpatient setting."

Data from this trial demonstrate that both study drugs were well tolerated. The incid
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:11/26/2014)... November 25, 2014 According ... by Power Source (Electric, Battery, Pneumatic), by Product ... Burr, Cart), by Application (Orthopedic, ENT, Oral, Thoracic, ... MarketsandMarkets, the global Powered Surgical Instruments Market is estimated ... in 2014 and is expected to grow at ...
(Date:11/26/2014)... 2014 Nanomix Inc., (Nanomix), a ... of mobile diagnostic tests to enable earlier ... pre-hospital settings, today announced it has received ... certification was awarded by the British Standards ... certification bodies. ISO 13485:2003 ...
(Date:11/26/2014)... THOUSAND OAKS, Calif. and LONDON ... AMGN ) and AstraZeneca (NYSE: AZN ) today ... trial evaluating two doses of brodalumab in more than 1,800 ... compared with both Stelara ® (ustekinumab) and placebo at ... the brodalumab weight-based analysis group were each shown to be ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... N.J., Dec. 22, 2011  Ikaria, Inc. announced today that ... DS drug-delivery systems related to a fretting corrosion.  This ... direction of the U.S. Food and Drug Administration (FDA).  ... a reasonable likelihood of serious adverse health consequences or ...
... 2011 ViroPharma Incorporated (NASDAQ: VPHM ) today ... acquire Meritage Pharma, Inc., a private company based in San ... a treatment for eosinophilic esophagitis (EoE), a chronic inflammatory disorder ... initial $7.5 million, and has agreed to provide Meritage up ...
Cached Medicine Technology:Ikaria® Issues Notice of Completed Remediation for INOMAX® DS Drug-delivery System 2Ikaria® Issues Notice of Completed Remediation for INOMAX® DS Drug-delivery System 3ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 2ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 3ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 4ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 5ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 6ViroPharma Purchases Exclusive Option to Acquire Meritage Pharma 7
(Date:11/27/2014)... In order to enable people to adapt to the ... way to avoid touching a toilet seat and/or lid while ... of the patent-pending Toilet Tamer, a device that enables a ... in a more sanitary manner. It avoids direct contact with ... promotes good hygiene and peace of mind. The portable device ...
(Date:11/27/2014)... 27, 2014 Now that Thanksgiving is ... officially launched, Emassagechair.com has announced its eagerly ... Event. , Negotiating on behalf of their customers, ... chair brands, Emassagechair.com has generated significant buzz in the ... biggest discounts yet. , Shoppers are excited for significant ...
(Date:11/27/2014)... VogueQueen.com is making every effort to offer more ... As the premier online supplier of elegant special occasion ... a huge selection of sexy prom dresses today. In ... providing many beautiful styles in its product line. Click ... prices. , “VogueQueen.com hopes to provide a truly unique ...
(Date:11/27/2014)... Developers and plugin specialist of Final Cut ... taking FCPX to the next level. , “ProPip allows users ... clicks of a mouse,” said Christina Austin, CEO of Pixel ... will appreciate.” , With ProPip users can show off their ... endless. ProPip is great for commentaries, news casting, and more. ...
(Date:11/27/2014)... November 27, 2014 HealthPostures, a ... ergonomics equipment , has announced that it has ... Office Environments. The partnership will put HealthPostures' products ... location. , In addition to having its products ... partnership promotes HealthPostures' products with the business decision ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... and Development, RESTON, Va., Feb. 4 ... that Donald W. Hackett, chief executive,officer, has left ... Bruce Roberts, RPh, executive vice president and ... chairman of Mirixa,s board of,directors, expressed appreciation for ...
... May Help Protect Your Heart, LANSING, Mich., Feb. ... mantras for promoting heart-health during February,American Heart Month. But ... red to protect our hearts. Americans are encouraged to ... first-ever National,Eat Red Week, Feb. 4-10., Why eat ...
... OTTAWA, Feb. 4 Sports and,nutritional product ... http://www.naturalnutritioninc.com primary operating subsidiary,InterACTIVE Nutrition, ... increase,in 2007 revenues over the calendar year ... (CDN) versus 2007 unaudited revenues of $17,460,780,(CDN)., ...
... Simcere Pharmaceutical,Group (NYSE: SCR ), a leading ... anti-cancer pharmaceuticals in the rapidly,growing China market, announced ... quarter results on Tuesday, March 4, 2008 before ... executive officer, Jinsheng Ren, and,chief financial officer, Frank ...
... SAN ANTONIO, Feb. 3 Noticing a few extra hairs ... trying to conceal areas of,thinning hair rather than a fashion ... promoting hair growth? If you answered,yes to any of these ... some form of hair loss. But to whom should you ...
... prove anecdotes that canines can smell dangerous drops in blood ... researchers hope to prove that a dog,s keen sense of ... sugar levels of diabetics. , Canines have already shown themselves ... the physically disabled with daily tasks. , But researchers at ...
Cached Medicine News:Health News:Mirixa Corporation Announces Leadership Change 2Health News:Celebrate American Heart Month by Eating Red 2Health News:Celebrate American Heart Month by Eating Red 3Health News:Natural Nutrition Operating Subsidiary Reports Record 29% Increase in Revenues for 2007 of $17,460,000 2Health News:Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008 2Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 2Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 3Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 4Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 5Health News:Don't Let Hair Loss Tangle You Up: Dermatologists Can Identify Common Hair Disorders and Offer Solutions 6Health News:Dogs Could Be a Diabetic's Best Friend 2Health News:Dogs Could Be a Diabetic's Best Friend 3Health News:Dogs Could Be a Diabetic's Best Friend 4
...
EDM Ventricular Drainage Kit, with Drip Chamber with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in ...
Lumbar External Drainage System (LED) with Touhy needle is indicated for temporary access to the Lumbar Subarachnoid region as a means of draining cerebral spinal fluid (CSF) in order to reduce incre...
Monitorr ICP external CSF drainage and monitoring system with patient line one way valve....
Medicine Products: